Business, energy, technology, markets and global industry news from Business News Today

Phase 2 trial

PharmaDeviceNews Phase 2 trial
Representative image of oncologists reviewing advanced gastric cancer imaging in a modern cancer care setting, reflecting Ono Pharmaceutical’s ONO-4578 Phase 2 data and the race to improve first-line treatment for HER2-negative gastric and gastroesophageal junction cancer.
Pharma & Biotech

Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?

Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.

Read More
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Pharma & Biotech

Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?

MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.

Read More
Pharma & Biotech

Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?

Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.

Read More
Pharma & Biotech

Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds

Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.

Read More
Pharma & Biotech

What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia

Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.

Read More
Pharma & Biotech

ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit

Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.

Read More
Pharma & Biotech

AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco

AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.

Read More
Pharma & Biotech

Serum Institute exits IXCHIQ rollout as Valneva resets LMIC strategy

Valneva ends its chikungunya vaccine deal with Serum Institute of India. Find out what this means for Asian access, LMIC rollout, and CEPI commitments.

Read More